Background: Complete revascularization is not possible in up to 37% of patients with coronary artery disease (CAD), these patients may benefit from the stimulation of neovascularization.
Aim: We evaluated the efficacy of therapeutic angiogenesis using basic fibroblast growth factor in patients with coronary artery disease (CAD).
Methods: in this double-blind, placebo-controlled Study eighteen patients with a severe diffuse atherosclerotic disease along the left anterior descending artery (LAD) who were a CABG candidate with at least one graftable coronary artery and the presence of ischemia and viable areas along the LAD were enrolled. During the CABG procedure in 10 patients, 10 FGF-2/alginate-heparin-sepharose microcapsules, each contains 100 mcg FGF-2, were implanted in the subepicardial layer of the diffusely defective LAD territory via 2-3 mm stab incisions.
Results: at least 7 patients in each group were followed for a period of 24 months. The result of left ventricular evaluation with echocardiography and perfusion scans showed significant improvement in FGF-2 receiving group with no significant change in controls, 3 and 6 months after the intervention. NYHA class was significantly lower in the intervention group (1.43±0.535 vs. 2.57±.535, P=0.002) and they remained free of angina 24 months after the intervention while 3 patients in the control group were hospitalized due to the acute chest pain (P > 0.05).
Conclusion: We revealed that FGF-2 improves the outcomes of patients with CAD undergoing CABG, without serious adverse effects.